Evidence map›Paper›PMID 28425033›Full record

ReviewCurrent cardiology reports2017

Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.

Ambuj Roy, Nitish Naik, K Srinath Reddy

Open access · hybridFull text readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current cardiology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Observational
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ambuj RoyPresident, Public Health Foundation of India, New Delhi, India.
Nitish NaikPresident, Public Health Foundation of India, New Delhi, India.
K Srinath ReddyPublic Health Foundation of India, Delhi National Capital Region, Plot No. 47, Sector 44, Institutional Area, Gurugram, 122002, India. ksrinath.reddy@phfi.org.
Public Health Foundation of India · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewPolypill and its role in cardiovascular disease (CVD) prevention has been extensively discussed and debated since the inception of the concept in 2003. This article reviews the subsequent accumulated research in this area. RECENT

findingsSeveral short and intermediate to long-term studies with different brands of polypills have analysed the impact of polypill in phase II and III trials. The strengths of polypill that have emerged include better adherence, equivalent or better risk factor control and quality of life among polypill users as compared to usual care. The lurking limitations include difficulty with dose adjustment to targets, fear of mass medicalisation and low acceptability among physicians. The current literature supports polypill use in reducing blood pressure and cholesterol levels for CVD prevention with improvement in adherence to medication. However, the long-term outcome of polypill on CVD events and mortality are unavailable and are currently being studied in clinical trials.

Indexed as

Antihypertensive AgentsCardiovascular AgentsCardiovascular DiseasesDrug CombinationsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMedication AdherencePlatelet Aggregation InhibitorsPrimary PreventionQuality of LifeRisk FactorsTreatment OutcomeAntihypertensive AgentsCardiovascular AgentsDrug CombinationsHydroxymethylglutaryl-CoA Reductase InhibitorsPlatelet Aggregation InhibitorsAdherenceCardiovascular diseasesFixed dose combinationPolypillPrimary preventionSecondary prevention

Identifiers

PMID28425033
PMCPMC5397453
OpenAlexW2606224605

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.